Fujifilm acquires all shares of Daiichi Radioisotope Laboratories,
a leading manufacturer of diagnostic radiopharmaceuticals.

Expands its medical imaging business into the area of nuclear medical imaging diagnosis and therapeutic radiopharmaceuticals

September 11, 2006

Fuji Photo Film Co., Ltd. (President: Shigetaka Komori, hereinafter “Fujifilm”) has decided to acquire all shares of Daiichi Radioisotope Laboratories, Ltd. (headquarters: Tokyo, hereinafter “DRL”), a leading manufacturer of diagnostic radiopharmaceuticals. DRL is a subsidiary of Daiichi Pharmaceutical Co., Ltd. (President: Kiyoshi Morita, hereinafter “Daiichi Pharmaceutical”) which is a wholly owned subsidiary of Daiichi Sankyo Co., Ltd. (President: Takashi Shoda, hereinafter “Daiichi Sankyo”). Fujifilm has concluded a share transfer agreement with Daiichi Pharmaceutical, and shares are scheduled for transfer on October 2, 2006, at which point DRL will start its operation as a wholly owned subsidiary of FUJIFILM Corporation. (*1).

(*1) FUJIFILM Corporation is a new operating company which will be established to take over the business of Fuji Photo Film Co., Ltd. upon its change to a holdings company structure on October 1, 2006.

Since its establishment in 1968, DRL has been involved with research, development, manufacture and sales of a broad range of products used in various types of examination, diagnosis and treatment as a pioneer of radiopharmaceuticals in Japan, and contributes to the development of nuclear medicine. Nuclear medicine using diagnostic radiopharmaceuticals is a highly safe method of examination which enables detection of changes in the functions of organs which may be caused by diseases before the morphological changes of organs occur. It plays a large role in diagnosing various types of heart and brain diseases, tumors as well as determining therapeutic strategy and prognosis.

Under the corporate philosophy of using leading-edge, proprietary technologies to “contribute to enhance the quality of life of people worldwide”, Fujifilm has globally expanded its medical imaging business, which have become one of its core businesses. Fujifilm has earned global recognition for developing the digital x-ray imaging diagnostic system FCR (Fuji Computed Radiography) and its Web-integrated PACS (Picture Archiving and Communications System) SYNAPSE network systems to store and process medical imaging information. An increasing number of health care facilities around the world have installed SYNAPSE, proving its high quality and reliability. Moreover, Fujifilm is actively expanding the business by offering a wide range of unique endoscopy products, which have also earned high acclaim. Among these is the “transnasal endoscope” that realizes high quality images using its proprietary imaging sensors, “Super CCD”, and image processing technology.

As a result of aging societies, there has been an exponential increase in ailments and the number of tests required to diagnose such ailments. Accordingly, medical professionals are demanding more efficient methods of examination as well as diagnosis and treatment with minimum physical burden, and it is believed that nuclear medicine will play a crucial role. While the areas of diagnosis and treatment become increasingly interdependent, functional diagnosis in order to realize early detection, early and patient-tailored treatments are becoming vital. Through this acquisition, Fujifilm's medical business will be expanded from the field of imaging that focused mainly on x-ray imaging diagnostic systems, to the closely related field of nuclear medicine including diagnostics (functional imaging) and therapeutics. The expansion will lead to a further growth in Fujifilm's medical imaging business. Fujifilm will enhance its medical business and continue its efforts to contribute to improvements in the quality and efficiency of medical care as well as people's health and quality of life.

Fujifilm is now making further headway toward new growth strategies that revolve around growing and prospective business fields including medical and life science businesses. The company is considerably strengthening its capital and R&D investments, while enlarging its new businesses through aggressive mergers and acquisitions. The acquisition of DRL is one facet of this growth strategy.

<Overview of Daiichi Radioisotope Laboratories, Ltd.>

Name: Daiichi Radioisotope Laboratories, Ltd.
President/CEO: Akiyuki Furuya
Location of HQ: Kyobashi 1-17-10, Chuo-ku, Tokyo
Establishment: December 5, 1968
Capital: 1.4 billion Yen
Revenues: 17.22 billion Yen (fiscal year ending March 31, 2006)
Number of employees:   420 (as of March 31, 2006)
Main products: Neuroimaging agents: Neurolite Injection Daiichi,
Iofetamine(123I) Injection Daiichi, Ultra-Techne Kow Cardiac imaging agents: Thallium Chloride Tl201 Injection, Cardiolite Injection Daiichi, MyoMIBG - I123 Injection Bone & tumor imaging agents: Techne MDP Injection, Gallium Citrate - Ga67 Injection Therapeutic agents for thyroid diseases: Sodium Iodide -131I Capsules

Media Contact:
Fuji Photo Film Co., Ltd.
Corporate Public Relations Division
Tel: 81-3-3406-2490
Fujifilm website:
Japanese : http://fujifilm.jp/
English : http://www.fujifilm.com/